| Name | Title | Contact Details |
|---|
Kaiser Inc is a Manteca, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioHitech America is the industry leader in the development of a simple, cost-effective food waste disposal technology designed to solve today’s landfill diversion and sustainability objectives. The Eco-Safe Digester handles food waste at the point of generation, no residual food waste to store or transport. The Eco-Safe Digester can convert up to 2,400 pounds of food waster per day into a nutrient-neutral grey water that can safely be disposed of via municipal sewer systems. The Eco-Safe Digester saves money by avoiding disposal costs and significantly reduces greenhouse gas emissions by providing a sustainable means of transportation for the waste by-product with doesn’t require on-road transportation. The Eco-Safe Digester’s cloud-based management solution is designed to measure and collect food waste data. It correlates information to report cost savings and environmental reductions as well as communicate opportunities to prevent waste altogether. This modifiable data can also be used to assess the performance of your staff and predict trends for smarter budgeting and purchasing purposes. In addition to diverting food waste from landfills and converting food waste into a resource, the machine is now poised for significant growth in this emerging data-driven zero waste initiative climate because it identifies waste in order to prevent the creation of it all together. Already implemented in many applications across the globe, the Eco-Safe Digester is ideal for use in any food service, hospitality, healthcare, government, conference center, education center, or stadium that generates a high volume of waste.
SaskWater is a Moose Jaw, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ImmusanT, Inc is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with Celiac disease.
The world leader in addiction treatment with over 20 years of experience and a patient-focused approach. We didn`t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They`re often unaware of their treatment options, have limited access to treatment, or simply don`t seek it out because they`re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, policy makers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like people with other chronic diseases. The past two decades have been marked by strong growth and an expansion into more than 40 countries. While treatment for opioid use disorder has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance addiction treatment including opiate overdose, alcohol use disorders, and co-occurring conditions such as schizophrenia by bringing to market novel treatment solutions worldwide. We at Indivior are on an endeavor – one that is focused on individual patients around the world. Our name reflects this as the key words individual and endeavor harmoniously blend together. It represents and empathizes with the often difficult journey each individual patient takes to overcome the challenges of addiction – a chronic relapsing disease. The patient continues to drive our decisions. Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit. We work with the urgency and zeal required to achieve our vision that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.